BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells

Abstract excerpt

Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients usually undergo surgery followed by aggressive radio- and chemotherapy with the alkylating agent temozolomide (TMZ). Still, median survival is only 12-15 months after diagnosis. Many human cancers including GBMs demonstrate addiction to MYC transcription factor signaling and can become susceptible to inhibition of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chromatin Remodeling and Cancer
• Share to Multiple Myeloma Research and Treatments
• Share to Protein Degradation and Inhibitors